A phase i dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 35-44

  Gillessen, Silke ^a   Gnad Vogt, Ulrike S ^b,i   Gallerani, Elisa ^c   Beck, Joachim ^d   Sessa, Cristiana ^c   Omlin, Aurelius ^a   Mattiacci, Maria R ^e,j   Liedert, Bernd ^b   Kramer, Daniel ^f   Laurent, Julien ^b,g   Speiser, Daniel E ^h   Stupp, Roger ^g  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b MERCK KGAA   (Germany)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e MERCK SERONO S A   (Switzerland)

^f Merck Serono Institute of Drug Metabolism and Pharmacokinetics   (Germany)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h Ludwig Center for Cancer Research   (Switzerland)

ⁱ CureVac GmbH   (Germany)

^j ACTELION PHARMACEUTICALS LTD   (Switzerland)

more..

Author keywords

Advanced solid tumours; Dose escalation; EMD 521873; Phase I; Selectikine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EMD 521873; INTERLEUKIN 2; MONOCLONAL ANTIBODY; SELECTIKINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANGIONEUROTIC EDEMA; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE THYROIDITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FEMALE; FEVER; HUMAN; HYPOTENSION; IMMUNOGENICITY; KIDNEY CARCINOMA; LEUKOCYTOCLASTIC VASCULITIS; LIMIT OF QUANTITATION; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NATURAL KILLER CELL; NAUSEA AND VOMITING; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; PSORIASIS; SKIN CARCINOMA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84871462134     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.015     Document Type: Article

References (31)

1. C.B. Davis, and S.D. Gillies Immunocytokines: amplification of anti-cancer immunity Cancer Immunol Immunother 52 2003 297 308 (Pubitemid 36578024)
2. J.C. Becker, J.D. Pancook, S.D. Gillies, K. Furukawa, and R.A. Reisfeld T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J Exp Med 183 5 1996 2361 2366 (Pubitemid 26158928)
3. C.S. Dolman, B.M. Mueller, H.N. Lode, R. Xiang, S.D. Gillies, and R.A. Reisfeld Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clin Cancer Res 4 10 1998 2551 2557 (Pubitemid 28477924)
4. J.A. Hank, J.E. Surfus, and J. Gan Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2) Clin Cancer Res 2 12 1996 1951 1959 (Pubitemid 27006627)
5. C. Grande, J.L. Firvida, V. Navas, and J. Casal Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma Anticancer Drugs 17 1 2006 1 12
6. M.B. Atkins, M.T. Lotze, and J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 7 1999 2105 2116 (Pubitemid 29318842)
7. M.B. Atkins, L. Kunkel, M. Sznol, and S.A. Rosenberg High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 6 Suppl. 1 2000 S11 4
8. D.M. King, M.R. Albertini, and H. Schalch Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients J Clin Oncol 22 22 2004 4463 4473 (Pubitemid 41185112)
9. K.L. Osenga, J.A. Hank, and M.R. Albertini A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group Clin Cancer Res 12 6 2006 1750 1759
10. Y.J. Ko, G.J. Bubley, and R. Weber Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer J Immunother 27 3 2004 232 239 (Pubitemid 39118088)
11. M. Johannsen, G. Spitaleri, and G. Curigliano The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Eur J Cancer 46 16 2010 2926 2935
12. J. Sharifi, L.A. Khawli, P. Hu, S. King, and A.L. Epstein Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors Hybrid Hybridomics 20 5-6 2001 305 312 (Pubitemid 34756999)
13. E.C. de Bruin, and J.P. Medema Apoptosis and non-apoptotic deaths in cancer development and treatment response Cancer Treat Rev 34 8 2008 737 749
14. D.R. Green Apoptotic pathways: the roads to ruin Cell 94 6 1998 695 698
15. M.S. Ricci, and W.X. Zong Chemotherapeutic approaches for targeting cell death pathways Oncologist 11 4 2006 342 357
16. S.Y. Proskuryakov, and V.L. Gabai Mechanisms of tumor cell necrosis Curr Pharm Des 16 1 2010 56 68
17. S. Chen, L. Yu, and C. Jiang Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer J Clin Oncol 23 7 2005 1538 1547
18. W.R. Shapiro, S.P. Carpenter, K. Roberts, and J.S. Shan (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma Expert Opin Biol Ther 6 5 2006 539 545 (Pubitemid 43723302)
19. H.H. Street, M.L. Goris, and G.A. Fisher Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer Cancer Biother Radiopharm 21 3 2006 243 256 (Pubitemid 44115194)
20. H. Wang, C. Cao, and B. Li Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients Cancer Immunol Immunother 57 5 2008 677 684 (Pubitemid 351641029)
21. S.D. Gillies, Y. Lan, and T. Hettmann A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity Clin Cancer Res 17 11 2011 3673 3685
22. S.D. Gillies, K.M. Lo, C. Burger, Y. Lan, T. Dahl, and W.K. Wong Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis Clin Cancer Res 8 1 2002 210 216 (Pubitemid 34101480)
23. K.K. Bass, and M.J. Mastrangelo Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer Cancer Immunol Immunother 47 1 1998 1 12 (Pubitemid 28430525)
24. S. Ben-Efraim Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity Curr Drug Targets 2 2 2001 197 212 (Pubitemid 32515039)
25. F. Ghiringhelli, C. Menard, and P.E. Puig Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 5 2007 641 648 (Pubitemid 46348738)
26. M.E. Lutsiak, R.T. Semnani, R. De Pascalis, S.V. Kashmiri, J. Schlom, and H. Sabzevari Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 7 2005 2862 2868 (Pubitemid 40446280)
27. J.S. Abrams, J.L. Eiseman, and T.J. Melink Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial J Immunother Emphasis Tumor Immunol 14 1 1993 56 64 (Pubitemid 23239941)
28. A. Ribas, J.M. Kirkwood, and M.B. Atkins Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma J Transl Med 7 2009 68
29. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
30. L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 1 2008 59 73
31. S. Shusterman, W.B. London, and S.D. Gillies Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study J Clin Oncol 28 33 2010 4969 4975